Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-09
2009-02-03
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253030, C514S290000
Reexamination Certificate
active
07485645
ABSTRACT:
In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17β-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 6362188 (2002-03-01), Guzi et al.
patent: 6541463 (2003-04-01), Labrie et al.
patent: 1122242 (2001-08-01), None
patent: WO 86/01105 (1986-02-01), None
patent: WO 90/10462 (1990-09-01), None
patent: WO 91/00731 (1991-01-01), None
patent: WO 91/00733 (1991-01-01), None
patent: WO 94/26767 (1994-11-01), None
patent: WO 96/26201 (1996-08-01), None
patent: WO 97/11162 (1997-03-01), None
patent: WO 99/46279 (1999-09-01), None
patent: WO 03/022835 (2003-03-01), None
patent: WO 03/033487 (2003-04-01), None
patent: WO 2004/046111 (2004-06-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Donald Poirier, Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases, 2003, Current Medicinal Chemistry, 10, pp. 453, 468 and 474.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Oct. 15, 1999, Science, 286, p. 531.
Golub, et al. “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”,Science, 286: 531-537 (Oct. 15, 1999).
Poirier, “Inhibitors of 17β-Hydroxysteroid Dehydrogenases”,Current Medicinal Chemistry, 10(6): 453-477 (2003).
Tsakovska, et al. “Molecular Modeling of Triazine Type MDR Modulators Using CoMFA and CoMSIA Approaches”,SAR and QSAR in Environmental Research13(3-4): 487-498 (2002).
Vippagunta et al. “Crystalline solids”, Advanced Drug Delivery Reviews, 48: 3-26 (2001).
International Search Report for PCT/US03/39863 for OC06001-01 dated May 11, 2004.
Doll Ronald J.
Girijavallabhan Viyyoor M.
Guzi Timothy J.
Liu Yi-Tsung
Pachter Jonathan A.
Bianchi Kristin
Farquharson-Torres Serena I.
Reinhardt Gerard E.
Saeed Kamal A
Schering Corporation
LandOfFree
17β-hydroxysteroid dehydrogenase type 3 inhibitors for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 17β-hydroxysteroid dehydrogenase type 3 inhibitors for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 17β-hydroxysteroid dehydrogenase type 3 inhibitors for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126453